Global law firm Hogan Lovells advised Villaris Therapeutics, a biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo, in a sale to global pharmaceutical company Incyte. Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize Villaris’ lead asset, monoclonal antibody auremolimab, for all uses, including for vitiligo and other autoimmune and inflammatory diseases. Further details can be found here.
Villaris’ shareholders will receive US$70 million in upfront payments and be eligible for up to US$310 million upon achievement of certain development and regulatory milestones, as well as up to an additional US$1.05 billion in commercial milestones on net sales of the product.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
